Autopsy report · NCT04158635

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

“Accrual Goal met”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 10 months before it started.
• Suspended: paused, and may or may not restart.
• 21 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

City of Hope Medical Center

Sponsor type

University, hospital or other

Conditions

Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma

Interventions

Bosentan; Gemcitabine; Nab-paclitaxel; Quality-of-Life Assessment; Questionnaire Administration

Participants

21 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
  “Unable to meet accrual goals” (75% match in meaning)
• Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer
  “No accrual” (70% match in meaning)
• Afatinib in Advanced Refractory Urothelial Cancer
  “Unable to meet accrual goal after several years” (68% match in meaning)
• Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
  “poor accrual” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.